PDCD1 and gastric cancer: For example, a study on gastric cancer reports that patients with low m6A score demonstrate a better survival benefit in STAD cohort and exhibit a markedly prolonged survival to checkpoint blockade therapy in both anti-PD-L1 cohort (IMvigor210) and anti-PD-1 cohort (GSE78220) (Zhang et al., 2020b).